Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan.


Journal

Journal of the Formosan Medical Association = Taiwan yi zhi
ISSN: 0929-6646
Titre abrégé: J Formos Med Assoc
Pays: Singapore
ID NLM: 9214933

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 27 12 2019
revised: 11 05 2020
accepted: 18 05 2020
pubmed: 6 6 2020
medline: 20 2 2021
entrez: 6 6 2020
Statut: ppublish

Résumé

Pathologic data of non-alcoholic fatty liver disease (NAFLD) was limited and the association between NAFLD and chronic hepatitis B remained unclear in Taiwan. This study aimed to determine the pathological manifestations of NAFLD and the impact of concurrent hepatitis B virus (HBV) infection in a medical center. Retrospective review of 104 consecutive random liver biopsies with the histologic diagnosis of NAFLD or cryptogenic cirrhosis from 2009 to 2018 was conducted. Clinical, biochemical and histological data were compared among various stages of NAFLD and between those with or without concurrent HBV infection. Advanced fibrosis was documented in 39.42% of Taiwanese patients with NAFLD according to METAVIR scoring system and was associated with aging (odds ratio, 1.06; 95% CI, 1.03-1.10), hypertension (odds ratio, 2.97; 95% CI, 1.31-6.74), diabetes mellitus (odds ratio, 4.36; 95% CI, 1.78-10.70) and concurrent HBV infection (odds ratio, 3.55; 95% CI, 1.46-8.58) by multivariate analyses. Concurrent HBV was found in 28.57% of the NAFLD patients. Patients with concurrent HBV had lower platelet counts, longer prothrombin time/INR and higher fibrosis stage than those without CHB. Advanced fibrosis in patients with NAFLD was common in the biopsy series, and was related to aging, hypertension, diabetes mellitus and concurrent HBV infection.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
Pathologic data of non-alcoholic fatty liver disease (NAFLD) was limited and the association between NAFLD and chronic hepatitis B remained unclear in Taiwan. This study aimed to determine the pathological manifestations of NAFLD and the impact of concurrent hepatitis B virus (HBV) infection in a medical center.
METHODS METHODS
Retrospective review of 104 consecutive random liver biopsies with the histologic diagnosis of NAFLD or cryptogenic cirrhosis from 2009 to 2018 was conducted. Clinical, biochemical and histological data were compared among various stages of NAFLD and between those with or without concurrent HBV infection.
RESULTS RESULTS
Advanced fibrosis was documented in 39.42% of Taiwanese patients with NAFLD according to METAVIR scoring system and was associated with aging (odds ratio, 1.06; 95% CI, 1.03-1.10), hypertension (odds ratio, 2.97; 95% CI, 1.31-6.74), diabetes mellitus (odds ratio, 4.36; 95% CI, 1.78-10.70) and concurrent HBV infection (odds ratio, 3.55; 95% CI, 1.46-8.58) by multivariate analyses. Concurrent HBV was found in 28.57% of the NAFLD patients. Patients with concurrent HBV had lower platelet counts, longer prothrombin time/INR and higher fibrosis stage than those without CHB.
CONCLUSION CONCLUSIONS
Advanced fibrosis in patients with NAFLD was common in the biopsy series, and was related to aging, hypertension, diabetes mellitus and concurrent HBV infection.

Identifiants

pubmed: 32499209
pii: S0929-6646(20)30217-5
doi: 10.1016/j.jfma.2020.05.027
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1476-1482

Informations de copyright

Copyright © 2020 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest There is no conflict of interest.

Auteurs

Hau-Jyun Su (HJ)

Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan.

Jia-Horng Kao (JH)

Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan; Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan. Electronic address: kaojh@ntu.edu.tw.

Tai-Chung Tseng (TC)

Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan; Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan.

Hung-Chih Yang (HC)

Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan; Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan.

Tung-Hung Su (TH)

Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan; Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan.

Pei-Jer Chen (PJ)

Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan; Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan.

Chun-Jen Liu (CJ)

Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan; Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan. Electronic address: cjliu@ntu.edu.tw.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH